Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly TV-1106 vs daily Genotropin in adult growth hormone deficiency
2014-002736-13Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of albusomatropin in adult onset growth hormone deficiency (AGHD) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Primary safety and tolerability endpoints. Started Mar 2015; status: terminated.
02
Drugs
albusomatropin
03
Conditions
adult onset growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on 2014-002736-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002736-13.